Filing Flows › Niagen Bioscience (NAGE) › R&D spending
Niagen Bioscience (NAGE) R&D spending by quarter
Niagen Bioscience's R&D spending was $1.8M in Q3 2026 (third quarter 2026), +19% from Q2 2026. Over the last 6 quarters it ranged from $1.3M (Q1 2025) to $1.8M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.8M | +19% | +0.1% |
| Q2 2026 | $1.5M | +2% | -3% |
| Q1 2026 | $1.5M | -17% | +18% |
| Q3 2025 | $1.8M | +15% | — |
| Q2 2025 | $1.6M | +25% | — |
| Q1 2025 | $1.3M | — | — |
Q3 2026 at a glance
Niagen Bioscience, Q3 2026: revenue $27.2M (-20% year over year), operating margin -5.8%, net loss $1.2M, operating cash flow $2.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Niagen Bioscience's R&D spending?
Niagen Bioscience's R&D spending was $1.8M in Q3 2026 (third quarter 2026), +19% from Q2 2026.
How has Niagen Bioscience's R&D spending changed?
Over the last 6 quarters it ranged from $1.3M (Q1 2025) to $1.8M (Q3 2026).